Zepp Health Corporation (ZEPP) Stock Price & Analysis
Zepp Health Corporation (ZEPP) — MoonshotScore 27/100 (Weak band), calculated Oct 26, 2026. Price $2.61 (-1.88%), as of the Oct 23, 2026 trading session; market cap $37.4M.
Educational signal · not a buy or sell recommendation · How to read this
Zepp Health Corporation · ZEPP · NYSE
Zepp Health Corporation specializes in developing and selling smart wearable devices, including smart bands and watches, primarily in China. The company operates under the Xiaomi and Amazfit brands, focusing on innovation in health and fitness technology.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore v2 · Zepp Health (ZEPP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but bottom-tier quality and a fragile balance sheet, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Falling.
- quarterly revenue $65M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 0 of 8
- Altman Z 0.12 · Piotroski F 5
Holding back: weak fundamentals, balance-sheet strain, weak price trend
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak |
The score was 27 in the stored Oct 24, 2026 snapshot and remains 27 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.61 | |
| Change on the day | -1.88% | |
| 52-week range | $2.23 – $47.27 | |
| Market capitalisation | $37.4M | |
| Price / earnings (trailing) | 107.20 | |
| Shares traded on the day | 80.0K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Zepp Health (ZEPP): Split View
36/100 · DCouncil is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 26, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the ZEPP film — every key number, told as a short cinematic story
~2 min · open the film
What is Zepp Health (ZEPP), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zepp Health Corporation (ZEPP) is listed on NYSE. It employs 763 people and is led by Wang Huang. In Q2 FY2026 it reported revenue of $65M and net income of -$12M. The market values it at $37.4M.
What do the latest results show for Zepp Health (ZEPP)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $65M. Against analyst estimates the company has EPS beat 0 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $65M | -$12M | -$11.80 (diluted) |
| Q1 FY2026 | $53M | -$20M | -$20.50 (diluted) |
| Q4 FY2025 | $90M | -$12M | -$11.58 (diluted) |
| Q3 FY2025 | $81M | -$2M | -$0.11 (diluted) |
What are the financial strengths and risks for Zepp Health (ZEPP)?
Short answer
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z 0.12 · Piotroski F 5. Trailing ratios: ROE -27.9% · ROA -7.9% · current ratio 0.90 · free-cash-flow yield -70.3%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.12 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-27.9%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
How does Zepp Health compare with its peers?
Short answer
Zepp Health's score ranks 10th of 12 in the bounded comparison shown, against 11 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $317.28 Oct 23, 2026 | $3.88T | 94 5-pillar Oct 26, 2026 | |
| $347.73 Oct 23, 2026 | $5.07T | 89 5-pillar Oct 26, 2026 | |
| $26.08 Oct 23, 2026 | $156B | 71 5-pillar Oct 26, 2026 | |
| $78.89 Oct 23, 2026 | $12.0B | 63 5-pillar Oct 26, 2026 | |
| $3.46 Oct 23, 2026 | $32.7M | 53 5-pillar Oct 26, 2026 | |
| $16.46 Oct 23, 2026 | $295M | 38 5-pillar Oct 26, 2026 | |
| $17.54 Oct 23, 2026 | $2.07B | 37 5-pillar Oct 26, 2026 | |
| $2.59 Oct 23, 2026 | $2.59B | 29 5-pillar Oct 26, 2026 | |
| $0.33 Oct 23, 2026 | $6.93M | 28 5-pillar Oct 26, 2026 | |
| Zepp Health (ZEPP) — this page | $2.61 | $37.4M | 27 |
| $2.06 Oct 23, 2026 | $174M | 23 5-pillar Oct 26, 2026 | |
| $1.01 Oct 23, 2026 | $208M | 18 5-pillar Oct 26, 2026 | |
| $6.93 Sep 10, 2026 | — | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Zepp Health (ZEPP)?
What Investors Ask About Zepp Health (ZEPP)
These answers are editorial: 1 of these 9 answers is drawn from the ZEPP research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ZEPP?
ZEPP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Zepp Health Corporation specializes in developing and selling smart wearable devices, including smart bands and watches, primarily in China.
Is ZEPP a good stock to buy?
Stock Expert AI does not rate ZEPP buy, sell or hold. Zepp Health Corporation carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZEPP stock price today?
The last price recorded on this page for Zepp Health Corporation (ZEPP) is $2.61, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ZEPP?
Zepp Health faces several risks, including intense competition from established brands like Apple and Fitbit, which could impact market share.
What are the key factors to evaluate for ZEPP?
Zepp Health Corporation (ZEPP) holds a MoonshotScore in the low range. P/E: 107.20x. No dividend yield, indicating a focus on reinvestment for growth rather than returning capital to shareholders. Not financial advice.
How frequently does ZEPP data refresh on this page?
ZEPP's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZEPP's recent stock price performance?
Zepp Health Corporation (ZEPP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong partnership with Xiaomi enhances brand visibility and distribution. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZEPP overvalued or undervalued right now?
Zepp Health Corporation (ZEPP) trades at 107.20x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZEPP before investing?
Before investing in Zepp Health Corporation (ZEPP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (17 figures)
The 17 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $2.61 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T08:44:38.166Z. | |
px.change | Change on the day | -1.88% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $37.4M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T20:00:02.000Z. Captured from FMP at 2026-10-26T08:44:36.488Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.05 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $65M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 107.20 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 80.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$12M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 0 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 0.12 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
px.range52 | 52-week range | $2.23 – $47.27 | UNRECORDED | Stored company-profile observation — Captured 2026-10-26 | |
id.employees | Employees | 763 | UNRECORDED | Stored company-profile observation — Captured 2026-10-26 | |
id.ceo | Chief executive | Wang Huang | UNRECORDED | Stored company-profile observation — Captured 2026-10-26 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -27.9% · ROA -7.9% · current ratio 0.90 · free-cash-flow yield -70.3% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 27 of 100 · Weak · pillars 23 / 10 / 51 / 69 / 13 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 27 (stored snapshot Oct 24, 2026) → 27 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.